Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Clinical Research

Background:

• Immune-related adverse events (irAEs) are common during immuno-oncology therapy for metastatic renal cell carcinoma (mRCC).
• These irAEs have been linked to improved clinical outcomes in mRCC patients.
• Specific irAEs and their prognostic significance require further investigation.

Purpose of the Study:

• To analyze the association between specific immune-related adverse events (irAEs) and the prognosis of patients with metastatic renal cell carcinoma (mRCC).
• To identify which irAEs are associated with improved progression-free survival (PFS) and overall survival (OS) in mRCC patients treated with nivolumab and ipilimumab.

Main Methods:

• Retrospective data collection from 153 eligible metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab.
• Cox proportional hazards analysis was performed to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS).

Main Results:

• Endocrine disorder-related irAEs were significant prognostic factors for improved PFS and OS.
• Rash-related irAEs were also identified as significant prognostic factors, particularly for improved OS.
• The most frequent irAEs observed were endocrine disorders (28.8%), rash (18.3%), pulmonary disorders (10.5%), and liver dysfunction (9.8%).

Conclusions:

• Rash and endocrine disorder-related irAEs serve as predictors of survival outcomes in mRCC patients receiving nivolumab and ipilimumab.
• Effective management of these specific irAEs is crucial for enhancing patient prognosis and treatment efficacy.